Protein kinase CK2 (formerly casein kinase II) is frequently upregulated in human cancers, and transgenic expression of CK2a in lymphocytes is oncogenic. Lymphomagenesis is dramatically acclerated by coexpression of a c-myc transgene, suggestive of a synergistic interaction between the kinase and the transcription factor. Since c-myc can be phosphorylated by CK2, we hypothesized that the synergy between CK2 and c-myc might be due to a functional interaction of the two molecules. Pharmacologic inhibition of CK2 activity in cell lines established from CK2a transgenic T cell lymphomas reduces their proliferation and concomitantly with this, the steady state levels of c-myc protein decline. This is caused by acclerated c-myc protein turnover, which occurs in a proteasome-dependent manner. Transfection of cells with sense or anti-sense CK2 constructs modulates c-myc protein levels in concert with the alteration in CK2 activity, validating the findings obtained using the kinase inhibitors. Thus, CK2 is a critical regulator of c-myc protein stability and of the proliferation of these T cell lymphomas.
Introduction
Protein kinase CK2 (CK2, formerly casein kinase II) is a regulatory serine-threonine kinase that is ubiquitously expressed in cells and is highly conserved (Allende and Allende, 1995; Boldyreff et al., 1993; Dobrowolska et al., 1999; Guerra et al., 1999; Krebs et al., 1988; Pinna, 1994) . CK2 is essential for cell survival in yeast (Glover, 1998; Snell and Nurse, 1994) . We have recently used homologous recombination to demonstrate that the a' catalytic subunit of the enzyme is essential for normal differentiation of male germ cells (Xu et al., 1999) . Dysregulated CK2 protein expression was first reported in a bovine pseudo-leukemia caused by a protozoan parasite (ole-MoiYoi et al., 1992) . A series of additional papers have documented its upregulation in many human cancers including leukemias (Daya-Makin et al., 1994; Faust et al., 1996; Gapany et al., 1995) , and solid tumors (Faust et al., 1996 (Faust et al., , 1999 Munstermann et al., 1990) including breast cancer (Landesman-Bollag et al., 2001) . We have utilized transgenic mice to demonstrate that dysregulated expression of CK2 contributes to lymphocyte transformation (Seldin and Leder, 1995) . Transgenic mice overexpressing the CK2a catalytic subunit in lymphocytes develop early thymic lymphomas that are clonal, indicating that one or more additional mutations are required for lymphocyte transformation. Some of the potential collaborating events have been defined in bi-transgenic models that have focused upon biochemical substrates of CK2, including overexpression of the T acute lymphocytic leukemia-1 transcription factor (Kelliher et al., 1996) or loss of function of the p53 tumor suppressor gene (Landesman-Bollag et al., 1998) . The most potent biological synergy that has been observed is in bitransgenic mice overexpressing CK2a and c-myc in lymphocytes; these mice develop primitive multiclonal lymphoid leukemias in utero and die within a few days of birth (Seldin and Leder, 1995) .
c-Myc is a nuclear transcription factor that is essential for mammalian development (Davis et al., 1993) . c-Myc is upregulated in many malignancies; in Burkitt and other lymphomas, translocations of c-myc into immunoglobulin or T cell receptor loci causes dysregulated expression in lymphocytes leading to transformation (e.g. Erikson et al., 1983) . This has been validated in transgenic mouse models (e.g. Harris et al., 1988; Schmidt et al., 1988) . In spite of this critical role for c-myc in development and in cancer, the transcriptional targets of c-myc have been difficult to elucidate. Genes that have an 'E box' and may be regulated by c-myc include carbamoyl aspartate decarboxylase, gadd 45 (Bush et al., 1998) , ornithine decarboxylase (Bello-Fernandez and Cleveland, 1992) , and telomerase (Wang et al., 1998) .
c-Myc expression is regulated in cells at transcriptional and post-transcriptional levels, and subtle disruption of this regulation may contribute to transformation (Penn et al., 1990; von Deimling et al., 1990) . In addition to exquisite control of transcription and mRNA stability, the c-myc protein itself turns over rapidly, being degraded by the ubiquitin-proteasome pathway (Bonvini et al., 1998; Gregory and Hann, 2000) . c-Myc is a phosphoprotein, and phosphorylation may regulate stability or interaction with other proteins or DNA. Threonine 58 and serine 62 in the amino terminus can be phosphorylated by glycogen synthase kinase-3 (GSK3) and mitogenactivated protein kinase (MAPK) respectively, acclerating protein degradation . Mutation of Thr58 occurs in tumors, stabilizing c-myc and contributing to transformation (Bahram et al., 2000; Henriksson et al., 1993; Salghetti et al., 1999) . CK2 has been reported to associate with c-myc in cells and phosphorylate it in the C-terminal PEST domain, in consensus sites between amino acids 240 -262 and amino acids 342 -439, but the functional consequence of this has not been determined (Bousset et al., 1993 (Bousset et al., , 1994 Luscher et al., 1989; Street et al., 1990) . In this study, we address the question of whether the potent synergy of CK2 and c-myc in lymphocyte transformation is due to a functional interaction between the kinase and the transcription factor.
Results

CK2 phosphorylates a c-Myc-GST fusion protein in vitro
The first step in determining whether CK2 and c-myc interact in the process of lymphocyte transformation was to confirm that CK2 is capable of phosphorylating c-myc directly. For these experiments, purified recombinant human c-Myc prepared as a GST fusion protein was incubated with recombinant CK2 holoenzyme in vitro. The c-Myc-GST potein but not GST alone was phosphorylated by the recombinant enzyme ( Figure 1 ). Two approaches were used in this and later experiments to confirm that phosphorylation was mediated by CK2. Firstly, [g-32 P]GTP was used in the phosphorylation reaction: CK2 is one of the few kinases capable of utilizing GTP as a phosphate donor. Secondly, two selective inhibitors of CK2 were used to block CK2 activity and c-myc phosphorylation. CK2 can be inhibited by the glycosaminoglycan heparin and by dichlororibofuranosylbenzimidazole (DRB); these drugs are relatively non-specific, the former being a polyanion that interacts with many enzymes on the basis of charge and the latter being a general inhibitor of transcription when used on intact cells. Thus, we employed two more selective inhibitors of CK2: apigenin (also known as chrysin), a flavonoid antioxidant (Critchfield et al., 1996 (Critchfield et al., , 1997 ; and emodin, an anthraquinone (Battistutta et al., 2000; Yim et al., 1999) . Though not completely specific (Agullo et al., 1997; Lin et al., 1997; Reddy et al., 1999; Yin et al., 1999) , CK2 is one of the few targets they are known to share, and thus phosphorylation reactions in which GTP can be employed that are blocked by these two chemically unrelated inhibitors are likely to be mediated by CK2. They are effective inhibitors of CK2 in vitro (Figure 1 ) and when used on intact cells in culture.
Apigenin and emodin inhibit CK2 activity in CK2a transgenic lymphoma cell lines
To study the potential interaction of CK2 and cmyc in lymphocyte transformation, we did not use cells from bi-transgenic CK2a-c-myc mice in which c-myc is upregulated through transgenic overexpression. Instead, we made use of T lymphoma cell lines from CK2a-p53 +/7 mice that express c-myc. To determine whether the CK2 inhibitors were effective in inhibiting CK2 activity in the intact cells, cultured lymphoma cells were treated with increasing doses of apigenin, emodin, or DMSO vehicle. After 3 h, lysates of the cells were prepared and CK2 activity was measured using a highly specific peptide substrate, RRREEETEEE, with [g-32 P]GTP as the phosphate donor. Apigenin reduced CK2 activity in a dose-dependent manner with an IC 50 of 25 mM (Figure 2a) . Emodin also inhibited CK2 activity in a dose dependent manner, with an IC 50 of 10 mM (Figure 2b ). Inhibition of CK2 by apigenin and emodin was not mediated through inhibition of mitogen-activated protein kinase (MAPK); phosphatidylinositol-3 kinase (PI3K), or protein kinase C (PKC), as specific inhibitors of those kinases (PD98059, bisindolylmaleimide, and Wortmannin) did not affect CK2 activity (Figure 2c ). In mouse C57 mg breast cancer cells transformed by the activity of the wnt oncogene, CK2 is upregulated and phosphorylates the wnt pathway transcriptional cofactor b-catenin; inhibition of CK2 activity accelerates the degradation of b-catenin in the cells (Song et al., 2000) . Thus, we hypothesized that CK2 phosphorylation of c-myc in lymphoma cells might play a similar role in regulating its degradation. In cells in which CK2 activity was inhibited using apigenin or emodin, we measured c-myc protein levels using Western blotting. Inhibiting CK2 with either apigenin ( Figure  3a ,b) or emodin (Figure 3c ,d) for 3 h reduced c-myc protein levels in a dose-dependent fashion. The IC 50 s for c-myc protein levels were very similar to the IC 50 s for CK2 activity shown in Figure 2 ; the time course of the drop in c-myc protein levels followed the time course of the reduction in CK2 activity closely (not shown). c-myc protein levels were not altered by treatment with inhibitors of the MAPK, PKC, or PI3K pathways ( Figure 3a) ; thus, again, the reduction in c-myc protein is likely mediated through inhibition of CK2 rather than via another kinase. Unfortunately, no antibody specific for the CK2 phosphorylation sites of c-myc exists so we could not directly confirm that phosphorylation at these sites was altered.
c-Myc protein turnover is accelerated by inhibition of CK2
To determine whether CK2 regulates c-myc protein synthesis or degradation, we inhibited CK2 in the presence of cycloheximide (CHX) to block new protein synthesis and measured c-myc levels over time. In the presence of 10 mg/ml CHX and with normal CK2 activity, c-myc had a half life of more than 20 min in the CK2a lymphoma cells (Figure 4a , left lanes), similar to the half life reported in a variety of other cell types (Gregory and Hann, 2000; Ramsay et al., 1984) . We found that emodin was ineffective at inhibiting CK2 on this time scale, presumably because it does not enter and equilibrate rapidly inside the cells. Therefore, the half-life experiments were carried out with apigenin only. When the cells were treated with 50 mM apigenin in the presence of cycloheximide, the half-life of c-myc decreased to less than 10 min ( Figure  4a , right lanes). The c-myc protein levels were scanned, normalized based on the b-actin loading in each lane, and plotted with respect to time 0 (Figure 4b ). This experiment was repeated three additional times with similar results: the mean half life of c-myc in cells treated with CHX alone was 21 min in the four experiments, which was reduced to a mean of 8 min with apigenin treatment (P50.05).
CK2 protects c-Myc from proteasomal degradation
Recently, c-myc has been reported to be degraded, at least in some cell types, by the proteasome pathway. We hypothesized that inhibition of CK2 activity might accelerate proteasome-mediated degradation of c-myc. To test this, cells were treated with 50 mM apigenin (Figure 5a ) or 10 -20 mM emodin ( Figure 5b ) for 3 h in the presence or absence of the 26S proteasome Figure 2 Apigenin and emodin reduce CK2 activity in lymphoma cell lines. Cells in culture were treated with kinase inhibitors for 3 h, then lysates were prepared. CK2 activity was measured using the specific peptide substrate RRREEETEEE (Kuenzel and Krebs, 1985) with [g-32 P]GTP as a phosphate donor. Samples were assayed in duplicate and results were expressed as mean and standard deviation. Apigenin (a) and emodin (b) inhibited CK2 activity in a dose-dependent fashion, with IC 50 s of approximately 25 and 10 mM respectively. The MAPK inhibitor PD98059 (PD) at 20 mM, the PKC inhibitor bisindolylmaleimideI (Bis) at 0.5 mM, and the PI3K inhibitor Wortmannin (WM) at 2 nM had no significant effect (NS) on CK2 enzyme activity, as determined by a two-tailed Student's t-test of the means (c) inhibitor MG132 used at 10 mg/ml. In the absence of CK2 inhibition, MG132 blocked the degradation of cmyc (Figure 5a, lane 3) . In long exposures of the autoradiogram, high molecular weight immunoreactive c-myc species consistent with ubiquitin conjugates of cmyc can be seen (Figure 5a and c, lower panels). With inhibition of CK2 either by apigenin or emodin in conjunction with MG132, c-myc is not reduced ( Figure  5a , lane 4 and Figure 5c , lanes 3 and 5), indicating that the accelerated degradation of c-myc with CK2 inhibition requires an intact proteasome pathway. Results of these drug treatments are quantitated in Figure 5b and d. We conclude that the lymphoma cell lines have a functional proteasome pathway for c-myc degradation and that inhibition of CK2 leads to c-myc degradation via this pathway.
CK2 inhibition reduces lymphoma cell proliferation
Both apigenin and emodin have been reported to arrest cell cycle progression and proliferation of cancer cells (Kamei et al., 1998; Trochon et al., 2000) . Since pharmacologic inhibition of CK2 reduces c-myc protein, which may play a role in cell cycle progression (Bosc et al., 1999; Pinna and Meggio, 1997) , we expected that the CK2 inhibitors would reduce proliferation of the CK2a lymphoma cell lines. Cells were treated either with apigenin or emodin overnight and the incorporation of [ 3 H]thymidine was determined for the final 4 h of the incubation. Both apigenin and emodin resulted in an inhibition of [ 3 H]thymidine incorporation in a dose dependent fashion, indicative of a reduction in cell proliferation (Figure 6 ). At the end of this treatment, c-myc levels remained low, and no reduction of cell viability was seen as assessed by microscopy and by propidium iodide staining (in which no increase in hypodiploid cells was seen, data not shown). The dose range for the reduction in thymidine incorporation was similar although not identical to the doses that reduced CK2 activity and c-myc protein levels in the short-term treatment experiments.
c-Myc protein levels correlate with CK2 expression in cells
To validate the results with the pharmacologic CK2 inhibitors, we sought to manipulate CK2 expression levels using genetic techniques in the CK2a lymphoma cell lines. Unfortunately, these cells cannot be efficiently transfected by electroporation, lipofection, DEAE dextran, or calcium phosphate techniques, and are also not efficiently infected using retroviruses (data not shown). Thus, we have used the EL4 murine T lymphoma cell line and the COS-7 cell line to determine whether genetic alteration of CK2 expression and activity leads to an alteration in c-myc protein levels. Transient transfection of EL4 cells with CK2a and CK2b sense or antisense plasmid constructs consistently led to up-and down-regulation of endogenous c-myc protein expression ( Figure 7a) ; Figure 3 Apigenin and emodin reduces c-myc protein levels in lymphoma cell lines. Cells in culture were treated for 3 h with apigenin or emodin, then lysates were prepared. C-myc protein levels were determined by Western blotting (a and c). The c-myc protein bands were scanned, normalized to b-actin levels, and plotted with respect to control lysates from cells treated with DMSO alone (b and d). Both apigenin and emodin reduced the amounts of the 67 kDa c-myc protein in a dose-dependent fashion. The MAPK inhibitor PD98059 (PD) at 20 mM, the PKC inhibitor bisindolylmaleimide (Bis) at 0.5 mM and the PI-3 kinase inhibitor Wortmannin (WM) at 2 nM did not have any affect on the levels of c-myc protein (a, lanes 6 -8) protein levels were quantitated, normalized with respect to b-actin levels, and compared with the alteration in CK2 activity in the same transfectants (Figure 7b) . In three experiments, up-or downregulation of c-myc protein levels occurred concomitantly with up-or down-regulation of CK2 activity, although the magnitude of the decrease with the antisense constructs was consistently greater than the magnitude of the increase with the sense constructs.
COS-7 cells were transfected with human c-Myc along with the sense or antisense constructs. In COS-7 cells, unlike the EL4 cells, the antisense constructs were ineffective in reducing CK2 activity and c-Myc protein levels. Transfection of the CK2a and b sense constructs with c-Myc increased c-Myc protein levels over and above the level achieved with the c-Myc construct alone; a representative experiment is shown ( Figure  8a) . Quantitation of the c-Myc protein levels and normalization for b-actin revealed the increase in cMyc protein to be 80% with CK2 overexpression; the increase in CK2 activity in the same lysates was 60% (Figure 8b) . Thus, c-Myc protein levels are regulated in coordination with CK2 activity in transfected EL4 and COS cell lines.
Discussion
Our results confirm previous reports that c-myc is a direct phosphorylation substrate of CK2 in vitro, but we have now identified the likely functional role of this phosphorylation in cells in vivo. Pharmacologic inhibition of CK2 reduces c-myc protein levels in lymphoma cell lines and leads to growth arrest of the cells, without any evidence of apoptosis. The results with the pharmacologic inhibitors was supported through molecular manipulation of CK2 expression levels and activity in cell lines, which also affected c-myc protein levels. Thus, CK2 activity is essential to the rapid proliferation of these lymphoma cell lines, perhaps through regulation of the levels of c-myc, although regulation of other CK2 substrates may also affect cell growth. In terms of the mechanism of reduction of cmyc, we find that CK2 inhibition accelerates the degradation of c-myc protein in CHX-treated cells in a proteasome-dependent manner, suggesting that normal CK2 phosphorylation of the C-terminal CK2 sites in the PEST domain of c-myc hinders susceptibility of c-myc to the action of the ubiquitinproteasome machinery. These results provide an important insight into the probable biological function and relevance of the CK2 sites in c-myc, but certainly do not exclude the possibility that CK2 acts upon another upstream regulator of c-myc or that CK2 regulates c-myc transcription or translation in addition to protein stability (since CK2 regulates a variety of basal and inducible transcriptional processes). The cmyc partner max is also a CK2 substrate, and DNA binding kinetics of max-containing complexes is enhanced by CK2 phosphorylation (Bousset et al., 1993 (Bousset et al., , 1994 , but the consequences of phosphorylation of c-myc itself had previously remained elusive.
These results are similar to what we have found for b-catenin, the key transcriptional cofactor in the wnt signaling pathway (Song et al., 2000) . Wnt signaling augments TCF/LEF signaling by stabilization of bcatenin levels, occurring through inhibition of the serine-threonine kinase GSK3b and reduction in Nterminal phosphorylation of b-catenin at serine 37. Wnt signaling also upregulates CK2 levels in mammary epithelial cells, and inhibition of CK2 activity accelerates b-catenin degradation. We have recently identified the major CK2 phosphorylation site in bcatenin to be threonine 393 (Song et al, unpublished) . Thus, N-terminal phosphorylation of b-catenin by GSK3-b promotes degradation while C-terminal phosphorylation by CK2 inhibits it. Analogously, GSK3-b phosphorylates c-myc at threonine 58 in the Nterminus, signaling ubiquitination and proteasomal degradation, and this is antagonized by C-terminal phosphorylation in the PEST domain by CK2.
Post-translational modification of c-Myc appears to be highly relevant to the pathogenesis of Burkitt lymphoma. While we consider this disease to be a consequence of gene rearrangements that juxtapose the c-Myc locus on chromosome 8 with immunoglobulin regulatory sequences, in fact, the rearrangement in and Figure 4 Apigenin accelerates c-myc protein degradation. The half life of c-myc protein was assessed by Western blot in the presence of 10 mg/ml CHX to block de novo protein synthesis. One representative experiment of four is shown (a). The c-myc protein bands were scanned, normalized to b-actin to control for loading, and plotted with respect to the level in untreated cells (b). In the absence of apigenin (CHX, a, lanes 2 -4, and b, white bars), cmyc had a half life of about 25 min. In the presence of 50 mM apigenin (CHX+Api; a, lanes 5 -7, and b black bars) the half life of c-myc was reduced to about 10 min of itself is insufficient to cause lymphoma. Transgenic mice expressing such rearranged mini-genes develop clonal lymphomas at a median of about 6 months of age (Harris et al., 1988) ; if overexpression of c-Myc alone was sufficient to transform lymphocytes, the mice would develop polyclonal lymphomas when lymphocytes first develop, prenatally. In human Burkitt lymphomas, additional mutations that promote c-Myc stability occur frequently, such as mutation of threonine 58 to alanine. One would predict that loss of GSK-3 b would be equally efficacious in stabilizing c-Myc protein, i.e. GKS-3 b could be a tumor suppressor gene in lymphoma. In contrast, since CK2 promotes c-Myc stability, upregulation of CK2 should be oncogenic. This is precisely what we have seen in the transgenic model in which co-expression of CK2 and c-Myc dramatically accelerate lymphomagenesis (Seldin and Leder, 1995) . Molecular therapeutic approaches to c-Myc-based malignancies might target kinases such as CK2 in addition to attempting to block the transcriptional activity of c-Myc itself.
The observation that c-Myc levels were dependent upon CK2 activity in COS cells as well as lymphocytes suggests that regulation of c-Myc stability by CK2 phosphorylation may be a general mechanism in a 
Materials and methods
Cell culture and treatments
The generation of CK2a-p53 +/7 double transgenic mice was discussed in detail elsewhere (Landesman-Bollag et al., 1998) . These mice developed thymic lymphomas by the age of 4 -6 months and cell lines were established from these by propagation in RPMI medium supplemented with 10% fetal bovine serum, 2% L-glutamine, 1% penicillin/streptomycin (Mediatech Inc., Herndon, VA, USA) and 1.4 mM bmercaptoethanol (American Bioanalytical, Natick, MA, USA). No additional growth factors were added in the medium. Cells were passaged every 2 -3 days as required to maintain log phase growth for all experiments. The pharmacologic experiments were carried out in three independent T cell lymphoma cell lines and gave similar results. Results with a single representative cell line are shown for each experiment. The EL4 murine lymphoma line was also maintained in RPMI supplemented with 10% fetal bovine serum, 2% L-glutamine, 1% penicillin/streptomycin and 1.4 mM b-mercaptoethanol. For pharmacologic experiments, the kinase inhibitors apigenin, Wortmannin, bisindolylmaleimide (Sigma, St Louis, MO, USA), and PD98059 (NEB, Inc., Beverly, MA, USA) were dissolved in dimethyl sulphoxide (DMSO). Bisindolylmaleimide was used at 1 mM, a dose that caused a 50% reduction in PKC activity in the cell lines, measured using a PKC Assay Kit (Upstate Biotechnology, Lake Placid, NY, USA). Wortmannin was used at 2 nM a dose that led to a 50% inhibition of proliferation as measured by [ 3 H]thymidine incorporation. These cell lines had very little MAPK activity and it was very difficult to measure the effect of PD98059; thus, PD98059 was Figure 7 Endogenous c-myc protein levels are altered in accord with up-or down-regulation of CK2 expression in EL4 lymphoma cells. EL4 lymphoma cells were transfected with an MSCV-GFP control plasmid or with MSCV-GFP-CK2a and b sense or antisense plasmids. Forty-eight hours after transfection, cell lysates were prepared and assayed for c-myc protein levels and CK2 activity. The cells transfected with the two sense constructs had an increase in c-myc protein expression while cells transfected with the two antisense constructs had a decrease in c-myc protein levels; a Western blot representative of three experiments is shown (a). The autoradiograms were scanned and the c-myc protein levels were normalized to b-actin levels; in this experiment an 8% increase and a 40% decrease in c-myc protein was seen (plotted in b, left bars). In the same cell extracts, transfection with the sense constructs resulted in a 10% increase in CK2 activity (which was not statistically significant) while transfection with the antisense constructs resulted in a significant (P50.02) decrease in CK2 activity of 24% (b, right bars) Figure 8 Exogenous c-Myc protein expression is upregulated by overexpression of CK2 in COS-7 cells. COS-7 cells were transfected with 5 mg of the CMV-c-Myc plasmid alone or with CMV-c-Myc along with 2.5 mg each of the MSCV-CK2a and b sense plasmids. Forty-eight hours after transfection, lysates were prepared and assayed for c-Myc protein levels by Western blotting; one representative experiment of three is shown (a). Quantitation and normalization to b-actin levels revealed an increase of 80% in c-Myc protein (b, gray bars). In the same lysates, an increase in CK2 activity of 60% was seen (b, white bars) used at a dose that inhibits human T cell proliferation by 75% (Dumont et al., 1998) . The proteasome inhibitor MG132 (Calbiochem, San Diego, CA, USA) was dissolved in DMSO and used at 10 mM final concentration. CHX was dissolved in ethanol and used at a concentration of 10 mg/ml to inhibit protein synthesis. All drug treatment experiments were carried out at least three times, with consistent results.
Plasmids and transfection
CK2a sense and CK2a antisense vectors were generated by cloning the 1.2 kb murine CK2a cDNA into BglII linearized MSCV-GFP vector, kindly provided by Dr B Nicolajczyk, Boston University School of Medicine. The orientation of CK2a was assessed by making use of HindIII sites which are present at 40 and 500 base pairs. CMV-c-Myc, consisting of the coding exons 2 and 3 for human c-Myc driven by a CMV promoter was obtained from Dr G Sonenshein, Boston University School of Medicine. EL4 cells were transfected with sense and antisense CK2a vectors by the DEAE dextran method (Grosschedl and Baltimore, 1985) . Briefly, 1610 7 cells were washed twice in PBS and then in TS buffer (1.4 M Nacl, 50 mM KCl, 4 mM Na 2 HPO 4 .7H 2 O and 240 mM Tris base, pH adjusted to 7.4) with MgCl 2 and CaCl 2 solution for 10 min at room temperature. Complexes were prepared using 5 mg of DNA and 0.05 ml of 10 mg/ml DEAE dextran in 0.95 ml of TS buffer and incubated at room temperaure for 10 min. Cells were resuspended in the DNA/ DEAE dextran complexes and incubated at room temperature for 15 min with gentle mixing. RPMI containing 5% fetal calf serum and 52 mg/ml of chloroquine was added for a further 30 min incubation and then the cells were transferred to RPMI with 10% fetal calf serum. The transfection efficiency was determined after 48 h by visualizing green fluorescence protein under a fluorescence microscope. COS-7 cells were transfected using Fugene reagent per manufacturer's suggestions. Briefly, Cos-7 cells were grown in 10 cm plates to 70% confluence and 4 ml of fresh DMEM containing 10% fetal calf serum was added on the day of transfection. Fugene and plasmid DNA were mixed at a 3:2 ratio by volume in serum-free medium and added to the cells. After 8 h, fresh medium was added. The transfection efficiency was determined after 48 h by visualizing green fluorescence protein under a fluorescence microscope.
In vitro phosphorylation of c-Myc-GST fusion protein
Purified human c-Myc-GST fusion protein was a kind gift of Dr Gail Sonenshein. Different amounts of c-Myc-GST fusion protein was incubated with 50 U of recombinant protein kinase CK2 in 12.5 ml of CK2 kinase buffer (100 mM Tris-Cl (pH 8.0), 100 mM NaCl, 50 mM KCl and 100 mM Na 3 VO 4 ) containing 5 mCi of [g-32 P]GTP at 378C for 30 min, with or without CK2 inhibitors. The kinase reactions were stopped by adding 7.5 ml of 26 sample buffer, boiling, and then centrifuging and applying to a 7.5% denaturing polyacrylamide gel. The gel was transferred onto a nitrocellulose membrane and exposed to X-ray film to visualize the g-32 P-GTP labeled proteins. Afterwards, Western blotting was performed as described below to identify the phosphorylated targets.
Antibodies and Western blot analysis
For Western blot analysis, nuclear extracts or whole cell lysates were prepared from unstimulated normal thymus or CK2a transgenic derived lymphoma lines. To extract cellular proteins, cells were lysed in buffer containing protease and phosphatase inhibitors (50 mM Tris-Cl (pH 7.6), 125 mM NaCl, 1% NP-40, 1 mM NaF, 1 mM PMSF, 1 mM Na 3 VO 4 , 10 mM sodium pyrophosphate and 1 mg/ml each of aprotinin, pepstatin, leupeptin and chymostatin). Protein concentrations were determined using the BCA protein assay. Fifty to 75 mg of protein was diluted in 26SDS sample buffer containing 2% b-mercaptoethanol and boiled for 10 min before loading on a 7.5% denaturing polyacrylamide gel. The gel was electrophoresed for 40 min at 100 V and then transferred to a nitrocellulose membrane (Schleicher and Schuell Inc, Keene, NH, USA) using a semi-dry electroblotter (Owl Scientific, Woburn, MA, USA). Membranes were blocked overnight at 48C in 5% non-fat dry milk with 0.05% Tween-20 (Sigma) in Tris-buffered saline at pH 7.5 (TBS-T). Proteins were detected using primary antibodies against c-myc (Santa Cruz) or CK2a (Stressgen) at the recommended dilutions and developed using goat anti-rabbit or anti-mouse antibodies conjugated to horseradish peroxidase (Santa Cruz) at 1:1000 dilution. An antibody against b-actin (Sigma) was used as a control for protein loading. Membranes were visualized using enhanced chemiluminescence reagent (Pierce) and quantitated on a BioRad densitometer using Quantity One software.
CK2 kinase assay
CK2 activity was measured in duplicate by incubating 5 mg of total protein with 1 mM of the synthetic CK2 substrate peptide (RRREEETEEE, Genosys Biotechnologies Inc.) in kinase buffer (100 mM Tris-Cl (pH 8.0), 100 mM NaCl, 50 mM KCl and 100 mM Na 3 VO 4 ) containing 100 mM [g-32 P]GTP for 15 min at 308C (Kuenzel and Krebs, 1985) . The reactions were stopped with 10 mM cold ATP and 0.4 N HCl and spotted onto P81 phosphocellulose filter discs (Whatman) that were washed three times for 5 min with 150 mM H 3 PO 4 to remove unincorporated radioactive nucleotide. The mount of phosphopeptide was quantitated on a beta counter. Background kinase activity in the absence of added peptide substrate was subtracted. 
Cell proliferation assay
